WALKERSVILLE, Md., and SAN DIEGO, June 13 /PRNewswire-FirstCall/ --
Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation
(NYSE: CBM), and Cytori Therapeutics (Nasdaq: CYTX) announced today that
they have entered into a strategic marketing agreement to provide
adipose-derived stem cell products globally for use in basic and
translational bioresearch.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )
Under the terms of the agreement, Cambrex Bio Science Walkersville,
Inc. will manufacture and market products to the research community under
the co-exclusive license from Cytori. In return for the license, Cytori
will receive royalties on all cells, media, and related future research
products based upon the licensed technology.
Adipose tissue is known to contain a rich population of stem and
progenitor cells that have been shown to possess significant regenerative
properties in multiple clinical disciplines. The licensing agreement brings
together Cambrex Bio Science Walkersville, Inc., a recognized leader in
providing high quality cells, media, information, and services to
researchers around the world, and Cytori, who is focused on developing
therapeutic applications for adipose stem and regenerative cells.
"Adipose tissue is now a validated source of regenerative cells," said
Shawn Cavanagh, Senior Vice President and General Manager, Cambrex
Bioproducts business. "The scientific potential of this population has only
begun to be mined, yet already shows promise in clinical case studies. We
look forward to offering the products to researchers that are conducting
basic and preclinical research related to these cells."
"Our relationship with Cambrex ensures that scientists and physicians
working on today's most challenging clinical problems including heart and
neurological diseases have readily available access to our cell
population," said Marc H. Hedrick, M.D., President of Cytori Therapeutics.
"Adipose is a dynamic tissue which, with further study, will help reveal
previously hidden biological insights that could be applied toward the
discovery of new therapies for a broad range of diseases."
Cambrex Corporation Forward Looking Statements
This news release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995 and Rule
3b-6 under The Securities Exchange Act of 1934, including, without
limitation, statements regarding expected performance, especially
expectations with respect to sales, research and development expenditures,
earnings per share, capital expenditures, acquisitions, divestitures,
collaborations, or other expansion opportunities. These statements may be
identified by the fact that words such as "expects", "anticipates",
"intends", "estimates", "believes" or similar expressions are used in
connection with any discussion of future financial and operating
performance.
The forward-looking statements contained herein are based on current
plans and expectations and involve risks and uncertainties that could cause
actual outcomes and results to differ materially from current expectations
including but not limited to, global economic trends, pharmaceutical
outsourcing trends, competitive pricing or product developments, government
legislation and/or regulations (particularly environmental issues), tax
rate, interest rate, technology, manufacturing and legal issues, changes in
foreign exchange rates, performance of minority investments, uncollectible
receivables, loss on disposition of assets, cancellation or delays in
renewal of contracts, and lack of suitable raw materials or packaging
materials, the possibility that the value of the acquisition of
PermaDerm(TM) cultured skin may not be realized or that our plans to obtain
a Humanitarian Device Exemption, completion of clinical trials and
commercialization of PermaDerm cultured skin in the United States may not
be successful, the Company may not receive regulatory approval for its
products, and the outcome of the evaluation of strategic alternatives.
For further details and a discussion of these and other risks and
uncertainties, investors are cautioned to review the Cambrex Annual Report
on Form 10-K, including the Forward-Looking Statement section therein, and
other filings with the Securities and Exchange Commission. The Company
undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise.
Cytori Therapeutics' Forward-Looking Statements
This press release includes forward-looking statements regarding
events, trends and prospects of our business which may affect our future
operating results and financial position. Such statements are subject to
risks and uncertainties that could cause our actual results and financial
position to differ materially. Some of these risks and uncertainties
include our history of operating losses and expected continuing losses, the
need for further financing, our ability to develop and commercialize
regenerative cell-based therapies, our dependence on third parties, our
ability to obtain, defend and enforce our intellectual property, and other
risks and uncertainties described (under the heading "Risk Factors") in
Cytori Therapeutics' Form 10-K annual report for the year ended December
31, 2005 and subsequent SEC filings, which will be available through our
web site. We assume no responsibility to update or revise any
forward-looking statements to reflect events, trends or circumstances after
the date they are made.
About Cambrex
Cambrex is a global, diversified life sciences company dedicated to
providing products and services to accelerate and improve the discovery and
commercialization of human therapeutics. The Company employs approximately
2000 worldwide. For more information, please visit http://www.cambrex.com.
About Cytori Therapeutics
Cytori Therapeutics, Inc., (Nasdaq: CYTX; Frankfurt: XMPA) is
discovering and developing proprietary cell-based therapeutics utilizing
adult stem and regenerative cells derived from adipose tissue, also known
as fat. The Company's investigational therapies target cardiovascular
disease, spine and orthopedic conditions, gastrointestinal disorders and
new approaches for aesthetic and reconstructive surgery. To facilitate
processing and delivery of adipose stem and regenerative cells, Cytori has
developed its proprietary regenerative cell processing system to isolate
and concentrate a patient's own stem and regenerative cells in about an
hour. This system will dramatically improve the speed in which personalized
cell-based therapies can be delivered to patients.
SOURCE Cambrex Corporation; Cytori Therapeutics
 back to top
Related links:
http://www.cambrex.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
http://www.prnewswire.com/comp/134219.html /
CONTACT:
Anne-Marie Hess, Senior Director, Investor
Relations and Corporate Communications, Cambrex Corporation,
+1-201-804-3062, Annemarie.hess@cambrex.com; Tom Baker, Director,
Investor Relations, Cytori Therapeutics, +1-858-875-5258,
Tbaker@cytoritx.com
|
